Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019028190) ANTI-IL1RAP ANTIBODIES
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/028190 International Application No.: PCT/US2018/044890
Publication Date: 07.02.2019 International Filing Date: 01.08.2018
IPC:
A61K 39/395 (2006.01) ,C07K 16/18 (2006.01) ,C07K 16/28 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
Applicants:
CITY OF HOPE [US/US]; 1500 E. Duarte Road Duarte, CA 91010-3000, US
Inventors:
MENG, Weixu; US
MARCUCCI, Guido; US
Agent:
HETZER-EGGER, Claudia, H.; US
ADAMS, Lisa; US
AMENDT, Kevin, C.; US
BAUER, John, A.; US
AZRIN, Linda, B.; US
Priority Data:
62/539,89501.08.2017US
Title (EN) ANTI-IL1RAP ANTIBODIES
(FR) ANTICORPS ANTI-IL1RAP
Abstract:
(EN) Provided herein are, inter alia, antibodies capable of binding Interleukin-1 receptor accessory protein (IL1RAP). The antibodies provided herein include novel light chain and heavy chain sequences and bind IL1RAP with high efficiency and specificity. The anti-IL1RAP antibodies provided herein are, inter alia, useful for the treatment of IL1RAP-expressing cancers such as AML.
(FR) L'invention concerne, entre autres, des anticorps qui peuvent se lier à la protéine accessoire du récepteur de l'interleukine-1 (IL1RAP). Les anticorps de l'invention comprennent de nouvelles séquences de chaînes légères et de chaînes lourdes et se lient à IL1RAP avec une efficacité et une spécificité élevées. Les anticorps anti-IL1RAP de l'invention s'utilisent, entre autres, pour le traitement de cancers exprimant IL1RAP, tels que la LMA.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)